2 weeks Ago By ABMN Staff
Corcept Therapeutics Incorporated ( NASDAQ:CORT – Free Report ) – Equities researchers at Zacks Research increased their Q1 2025 EPS estimates for Corcept Therapeutics in a report issued on Wednesday, September 25th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.
29 per share for the quarter, up from their prior estimate of $0.27. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.
12 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.
37 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.43 EPS and Q1 2026 earnings at $0.
46 EPS. Corcept Therapeutics ( NASDAQ:CORT – Get Free Report ) last announced its earnings results on Monday, July 29th. The biotechnology company reported $0.
32 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.09.
Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%.
The firm had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $155.14 million.
During the same quarter in the previous year, the business posted $0.25 EPS. The company’s quarterly revenue was up 39.
1% on a year-over-year basis. Get Our Latest Stock Report on CORT Corcept Therapeutics Stock Performance Shares of CORT opened at $43.93 on Friday.
Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $44.37.
The company’s fifty day moving average is $36.39 and its 200 day moving average is $30.68.
The stock has a market capitalization of $4.57 billion, a PE ratio of 41.44 and a beta of 0.
45. Insider Activity at Corcept Therapeutics In other news, insider William Guyer sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $38.
67, for a total value of $386,700.00. Following the sale, the insider now owns 6,039 shares in the company, valued at $233,528.
13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . In other Corcept Therapeutics news, insider William Guyer sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 1st.
The stock was sold at an average price of $38.67, for a total value of $386,700.00.
Following the completion of the transaction, the insider now directly owns 6,039 shares of the company’s stock, valued at $233,528.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink .
Also, insider Gary Charles Robb sold 3,101 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.
71. Following the sale, the insider now directly owns 23,190 shares in the company, valued at approximately $828,114.90.
The disclosure for this sale can be found here . Insiders sold 30,451 shares of company stock worth $1,090,844 over the last three months. Company insiders own 20.
50% of the company’s stock. Institutional Investors Weigh In On Corcept Therapeutics Several hedge funds have recently modified their holdings of CORT. Nisa Investment Advisors LLC increased its stake in shares of Corcept Therapeutics by 10.
5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 510 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Corcept Therapeutics by 0.
4% in the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock valued at $4,138,000 after buying an additional 541 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Corcept Therapeutics by 90.
6% during the 1st quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after buying an additional 579 shares during the period. Bank of Montreal Can lifted its position in shares of Corcept Therapeutics by 5.
0% during the 2nd quarter. Bank of Montreal Can now owns 12,156 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 580 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Corcept Therapeutics by 1.
9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,780 shares of the biotechnology company’s stock valued at $1,585,000 after acquiring an additional 932 shares during the period. 93.
61% of the stock is owned by hedge funds and other institutional investors. About Corcept Therapeutics ( Get Free Report ) Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Further Reading Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
